Liquid, Aqueous Pharmaceutical Composition of Factor VII Polypeptides

a technology of factor vii and aqueous pharmaceutical composition, which is applied in the direction of peptide/protein ingredients, inorganic non-active ingredients, extracellular fluid disorder, etc., can solve the problems of reducing activity, increasing immunogenicity, and lowering activity, so as to improve stability

Inactive Publication Date: 2010-07-01
NOVO NORDISK HEALTH CARE AG
View PDF69 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0013]The present inventors have discovered that Factor VII or analogues thereof (“Factor VII polypeptides”), when formulated as liquid, aqueous pharmaceutical compositions together with at least one metal-containing agent wherein said metal is selected from the group consisting of first transition series metals of oxidation state +II, except zinc, exhibit improved stability and thereby allow for prolonged storage before actual use.

Problems solved by technology

While the possible occurrence of protein instabilities is widely appreciated, it is impossible to predict particular instability problems of a particular protein.
Any of these instabilities can result in the formation of a protein by-product, or derivative, having lowered activity, increased toxicity, and / or increased immunogenicity.
Indeed, protein precipitation may lead to thrombosis, non-homogeneity of dosage form and amount, as well as clogged syringes.
Thus, no liquid ready-for-use- or concentrated Factor VII products are currently commercially available.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

working examples

Example 1

[0132]Effect of addition of copper-containing and manganese-containing agents to aqueous rFVIIa solutions on heavy chain degradation (autocatalytic cleavage)

[0133]In order to investigate the effect of metal ions on rFVIIa, the following procedure was followed:

[0134]rFVIIa was transferred to the following solutions by desalting on a PD-10 column (Amersham Biosciences):

rFVIIa1.0mg / mLSodium chloride2.92mg / mL (50 mM)Calcium chloride 2 H2O1.47mg / mL (10 mM)PIPES15.12mg / mL (50 mM)1 M NaOHadded to pH 6.5

[0135]Two solutions of metal-containing agents were prepared:

Copper(II) chloride, 2 H2O10 mMManganese chloride, 2 H2O 2 M

[0136]The copper-containing and manganese-containing agents, respectively, were added to the desalted rFVIIa solution in order to reach the concentrations outlined in Table 1. pH vas adjusted to 6.5. The formulations were stored at a temperature of 5° C. and analyses were performed at the times indicated in Table 1.

TABLE 1Content of Heavy chain degradation product...

example 2

[0140]Addition of copper-containing and manganese-containing agents and to aqueous rFVIIa solutions at high ionic strength

[0141]In order to investigate the effect of metal ions and high ionic strength on the stability of rFVIIa, the following procedure can be followed:

[0142]rFVIIa is transferred to the following solutions by desalting on a PD-10 column (Amersham Biosciences):

Sodium chloride2.92mg / mL (50 mM)Calcium chloride 2 H2O29.4mg / mL (200 mM)PIPES15.12mg / mL (50 mM)Poloxamer 1881.0mg / mLMethionine0.5mg / mL1 M NaOH / 1 M HCladded to pH 6.5and / orSodium chloride29.2mg / mL (500 mM)Calcium chloride 2 H2O1.47mg / mL (10 mM)PIPES15.12mg / mL (50 mM)Poloxamer 1881.0mg / mLMethionine0.5mg / mL1 M NaOH / 1 M HCladded to pH 6.5

[0143]In both solutions the concentration of Factor VIIa (rFVIIa) is 1.0 mg / mL

[0144]Two solutions of metal-containing agents are prepared:

Copper(II) chloride, 2H2O10 mMManganese chloride, 2 H2O 2 M

[0145]The copper-containing and manganese-containing agents, respectively, are added t...

example 3

[0147]Addition of copper-containing agents to aqueous rFVIIa solutions with high ionic strength.

[0148]In order to investigate the possible synergistic effect of metal ions and high ionic strength on the stability of rFVIIa, the following procedure was followed:

[0149]rFVIIa was transferred into various solutions (formulations) as listed in table 1 below in a two step process:

[0150]First, rFVIIa was transferred into the various solutions without copper added by desalting on a PD-10 column (Amersham Biosciences). Next, the copper content was obtained in solution 2 and 4 by adding a solution of 10 mM Copper(II) chloride, 2H2O until the stated concentration was reached.

[0151]After the copper solution had been added, pH was adjusted to 6.5 and the formulations were filled in cartridges.

[0152]The cartridges were stored at a temperature of 5° C. and analyses were performed after 0, 0.5, 1, 2, and 3 months as indicated in table 2.

TABLE 1FormulationsFormulations1234rFVIIa1.0mg / ml1.0mg / ml1.0mg...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
ionic strengthaaaaaaaaaa
pHaaaaaaaaaa
Login to view more

Abstract

The present invention is directed to liquid, aqueous pharmaceutical compositions containing Factor VII polypeptides, and methods for preparing and using such compositions, as well as vials containing such compositions, and the use of such compositions in the treatment of a Factor VII-responsive syndrome, e.g., bleeding disorders, including those caused by clotting Factor deficiencies (e.g. haemophilia A, haemophilia B, coagulation Factor VII deficiency); by thrombocytopenia or von Willebrand's disease, or by clotting Factor inhibitors, and intra cerebral haemorrhage, or excessive bleeding from any cause. The preparations may also be administered to patients in association with surgery or other trauma or to patients receiving anticoagulant therapy. More particularly, the invention relates to liquid compositions stabilised against chemical and / or physical degradation. The main embodiment is represented by a liquid, aqueous pharmaceutical composition comprising a Factor VII polypeptide (i); a buffering agent (ii) suitable for keeping pH in the range of from about 4.0 to about 9.0; at least one metal-containing agent (iii), wherein said metal is selected from the group consisting of first transition series metals of oxidation state +II, except zinc, such as chromium, manganese, iron, cobalt, nickel, and copper; and a non-ionic surfactant (iv).

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation of U.S. application Ser. No. 11 / 304,427, filed Dec. 15, 2005, which is a continuation of International application No. PCT / DK2004 / 000465 filed Jun. 30, 2004 and claims priority of Danish application No. PA 2003 00995 filed Jul. 1, 2003, priority of U.S. application No. 60 / 485,334 filed Jul. 7, 2003, and priority of International application No. PCT / DK2004 / 000181 filed Mar. 18, 2004.FIELD OF THE INVENTION[0002]The present invention is directed to liquid, aqueous pharmaceutical compositions containing Factor VII polypeptides, and methods for preparing and using such compositions, as well as containers containing such compositions, and the use of such compositions in the treatment of a Factor VII-responsive syndrome. More particularly, the invention relates to liquid compositions stabilised against chemical and / or physical degradation.BACKGROUND OF THE INVENTION[0003]A variety of Factors involved in the blo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/48A61P7/04A61K33/24A61K47/02A61K47/26
CPCA61K9/0019A61K33/24A61K33/26A61K33/32A61K33/34A61K38/4846A61K45/06A61K47/02A61K47/10A61K47/183A61K2300/00A61K47/20A61P7/04
Inventor JENSEN, MICHAEL BECHHANSEN, BIRTHE LYKKEGAARDKORNFELT, TROELSJACOBSEN, KRISTEN KRAMER
Owner NOVO NORDISK HEALTH CARE AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap